SSA
CTXR icon

Schonfeld Strategic Advisors’s Citius Pharmaceuticals CTXR Stock Holding History

Schonfeld Strategic Advisors’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-3,104
Closed -$45.3K – 2104
2024
Q2 		$45.3K Buy
+3,104
New +$55.6K ﹤0.01% 1944

Other funds holding CTXR

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
CCC
Chelsea Counsel Company Los Angeles, California $225M AUM 45.99% 1-Year Est. Return

Schonfeld Strategic Advisors's CTXR Position: Q3 2024 in Review

Schonfeld Strategic Advisors sold out of Citius Pharmaceuticals (CTXR) in Q3 2024, closing a stake of 3,104 shares — an estimated $45.3K sold.

Schonfeld Strategic Advisors first reported a position in CTXR in Q2 2024 and held it in 1 quarter. The position peaked at $45.3K in Q2 2024. 57 funds tracked by Wall St. Rank hold CTXR as of Q3 2024.

  • Schonfeld Strategic Advisors reported no remaining Citius Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 3,104 Citius Pharmaceuticals shares in Q3 2024, an estimated $45.3K.
  • Schonfeld Strategic Advisors first reported a position in Citius Pharmaceuticals in Q2 2024 and held it in 1 quarter.
  • Schonfeld Strategic Advisors's Citius Pharmaceuticals position peaked at $45.3K in Q2 2024.
  • 57 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q3 2024.

Based on Schonfeld Strategic Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.